Lung cancer patients with diabetes tend to live longer than patients without diabetes, according to a Norwegian study published in the November issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.
Researchers did not speculate on the reason for the effect, but said that the survival benefit warranted more study and that diabetes should not be considered a reason to withhold standard cancer treatment.
"Standard therapy should not be withheld from patients with diabetes mellitus provided they are otherwise fit, even if it may be considered a significant comorbidity," researchers wrote in the study. "The survival benefit may be of clinical importance and should be focused on in future studies."
Researchers at the Norwegian University of Science and Technology and Trondheim University analyzed 1,677 lung cancer cases from the Nord-Trøndelag Health study (HUNT), the pemetrexed gemcitabine (PEG) study and the Norwegian Lung Cancer Biobank study. It was the first cohort study from a well-defined geographical area, with a stable and large number of inhabitants, investigating lung cancer, diabetes and survival.
They found that the 1-, 2-, and 3-year survival in patients with lung cancer with and without diabetes mellitus were 43% versus 28%, 19% versus 11%, and 3% versus 1%, respectively.
The fact that patients with diabetes mellitus showed a lower frequency of metastatic diseases may partly explain the survival benefit in patients with diabetes mellitus, because the majority of the patients with lung cancer die of metastasis and not of the primary tumor," researchers wrote. "However, as we adjusted for stage of disease in our analyses this potential advantage can hardly explain the observed increased survival in patients with diabetes mellitus. In addition, increased survival in patients with diabetes mellitus was clearly demonstrated in the PEG study where all patients had advanced lung cancer."
About the Journal of Thoracic Oncology:
The Journal of Thoracic Oncology (JTO) is the official monthly journal of the International Association for the Study of Lung Cancer (IASLC). It is a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer. It emphasizes a multidisciplinary approach, including original research (clinical trials and translational or basic research), reviews and opinion pieces.
To learn more about the JTO please visit http://journals.lww.com/jto/pages/default.aspx.
About the IASLC:
The Denver-based International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association's membership includes more than 3,500 lung cancer specialists in 80 countries.
IASLC members promote the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and thoracic malignancies. IASLC disseminates information about lung cancer to scientists, members of the medical community and the public, and uses all available means to eliminate lung cancer as a health threat for the individual patients and throughout the world. Membership is open to any physician, health professional or scientist interested in lung cancer.
To learn more about IASLC please visit http://iaslc.org/
Journal of Thoracic Oncology